Charles Schwab’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.77M | Buy |
588,411
+215,558
| +58% | +$1.38M | ﹤0.01% | 2452 |
|
|
2025
Q1 | $1.32M | Buy |
372,853
+73,904
| +25% | +$262K | ﹤0.01% | 2747 |
|
|
2024
Q4 | $1.13M | Sell |
298,949
-3,321
| -1% | -$12.6K | ﹤0.01% | 2875 |
|
|
2024
Q3 | $979K | Sell |
302,270
-219,349
| -42% | -$711K | ﹤0.01% | 2923 |
|
|
2024
Q2 | $991K | Buy |
521,619
+85,716
| +20% | +$163K | ﹤0.01% | 2940 |
|
|
2024
Q1 | $1.24M | Buy |
435,903
+48,283
| +12% | +$137K | ﹤0.01% | 2725 |
|
|
2023
Q4 | $5.71M | Buy |
387,620
+21,758
| +6% | +$320K | ﹤0.01% | 2252 |
|
|
2023
Q3 | $6.7M | Buy |
365,862
+40,380
| +12% | +$739K | ﹤0.01% | 2115 |
|
|
2023
Q2 | $7.02M | Buy |
325,482
+5,396
| +2% | +$116K | ﹤0.01% | 2072 |
|
|
2023
Q1 | $9.39M | Buy |
320,086
+2,367
| +0.7% | +$69.4K | ﹤0.01% | 1904 |
|
|
2022
Q4 | $11.7M | Buy |
317,719
+76,980
| +32% | +$2.84M | ﹤0.01% | 1772 |
|
|
2022
Q3 | $6.78M | Buy |
240,739
+170,330
| +242% | +$4.79M | ﹤0.01% | 2055 |
|
|
2022
Q2 | $1.36M | Sell |
70,409
-2,618
| -4% | -$50.5K | ﹤0.01% | 2685 |
|
|
2022
Q1 | $939K | Buy |
+73,027
| New | +$939K | ﹤0.01% | 2874 |
|